Table 1. Drugs and drug candidates for treating Cryptosporidium infection in young children.

Compound	Development stage	Activity against Cryptosporidium	References
Nitazoxanide	FDA approved for Cryptosporidium, launched	Clinical	[40,44–46]
Nitazoxanide + Azithromycin	Proposed combination therapy	Anecdotal clinical evidence	[47–48]
Pyrvinium pamoate	Repurposing candidate (FDA approved for pinworm infections)	Animal model	[49]
Pitavastatin	Repurposing candidate (FDA approved for hypercholesterolemia)	In vitro only (yet to be tested in an animal model)	[50]
Auranofin	Repurposing candidate (FDA approved for rheumatoid arthritis)	In vitro only (yet to be tested in an animal model)	[51]
Calcium-dependent protein kinase 1 inhibitors	Preclinical	Animal model	[52]
Inosine 5’- monophosphate dehydrogenase (IMPDH) inhibitors	Preclinical	Animal model	[53]
Fatty acyl-CoA synthetase inhibitor Triacsin C	Preclinical	Animal model	[54]
Oleylphosphocholine	Preclinical	Animal model	[55]
Medicines for Malaria Venture (MMV) Malaria Box compounds	Preclinical	In vitro only (yet to be tested in an animal model)	[56]